SBIR Phase II: High Speed Sequencing and Structure Analysis

SBIR 第二阶段：高速测序和结构分析

• 批准号: 0450640
• 负责人: Jack Syage
• 金额: --
• 依托单位: SYAGEN TECHNOLOGY INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-05-15 至 2009-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0450640&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Speed; Sequencing

This Small Business Innovation Research (SBIR) Phase II project proposes to develop new methods for achieving high-speed sequencing and structure analysis of drug and biological molecules . The benefits of high-speed Molecular Sequencing (MSn) will be broadly applicable to end users through compatibility with ion trap MS instruments in general and specifically for the proposed QitTof MS (quadrupole ion - trap, time - of - flight mass spectrometry), which will provide the highest potential analysis speeds. The technical objectives for Phase II research are to (a) to develop high-speed MSn algorithms, (b) to optimize accurate mass neutral loss performance, (c) to develop CE / ESI (capillary electrophoresis / electrospray ionization) interface, and (d) to demonstrate CE / ESI / QitTof MS/MS for high-speed peptide sequencing. The final outcome of this Phase II work will be an instrument that will clearly achieve the highest speeds for peptide sequencing and overall protein identification. The commercial application of this project will be in the area of proteomics. The proteomics market is forecasted to grow from $ 0.7 billion to $ 5.8 billion over the next 5 years. There is a tremendous need to develop automated methods for the analysis of proteins and peptides linked to specific cells and tissues, in order to better understand global biological function for improved drug therapy and early detection of diseases such as cancer.

该小企业创新研究（SBIR）二期项目旨在开发实现药物和生物分子高速测序和结构分析的新方法。高速分子测序（MSn）的好处将广泛适用于最终用户，通过与离子阱质谱仪器的兼容性，特别是拟议的QitTof质谱（四极离子阱，飞行时间质谱），这将提供最高的潜在分析速度。二期研究的技术目标是：(a)开发高速MSn算法，(b)优化准确的质量中性损失性能，(c)开发CE / ESI（毛细管电泳/电喷雾电离）界面，(d)验证用于高速肽测序的CE / ESI / QitTof MS/MS。第二阶段工作的最终结果将是一种仪器，它将明显实现肽测序和整体蛋白质鉴定的最高速度。该项目的商业应用将在蛋白质组学领域。蛋白质组学市场预计将在未来5年内从7亿美元增长到58亿美元。为了更好地了解全球生物功能，以改进药物治疗和早期发现癌症等疾病，迫切需要开发自动化方法来分析与特定细胞和组织相关的蛋白质和多肽。